IMNM · Immunome Inc. · Executive Compensation
$20.90
+0.01 (+0.05%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$2.43B
Shares
113.58M
Volume · Oct 2
1.17M
Avg daily vol (3M)
1.2M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Clay Siegall | President, Chief Executive Officer and Chairman of the Board | $14,866,831 |
| Bob Lechleider | Chief Medical Officer | $2,915,362 |
| Jack Higgins | Chief Scientific Officer | $1,840,854 |
| Purnanand D. Sarma | Former Chief Executive Officer | $1,437,295 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Purnanand D. Sarma | Former Chief Executive Officer | $990,309 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dennis H. Giesing | Chief Development Officer | $3,499,917 |
| Corleen M. Roche | Chief Financial Officer | $3,096,344 |
| Purnanand D. Sarma | President, Chief Executive Officer and Director | $2,111,914 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Purnanand D. Sarma | President, Chief Executive Officer and Director | $1,695,002 |
| Sandra Stoneman | Chief Legal Officer and General Counsel | $1,314,397 |
| Michael J. Morin | Chief Scientific Officer | $936,806 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael J. Morin | Chief Scientific Officer | $363,770 |
| Purnanand D. Sarma | President, Chief Executive Officer and Director | $339,910 |
| Sandra Stoneman | Chief Legal Officer and General Counsel | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Bob Lapetina | Vice President, Finance, Corporate Controller, and principal accounting officer | Resigned | 2024-04-30 |
| Sandra Swain, M.D. | Class III director | Appointed | 2024-04-25 |
| Carol Schafer | Class I director | Appointed | 2024-01-02 |
| Bob Lapetina | principal accounting officer | Appointed | 2023-12-29 |
| Max Rosett | Interim Chief Financial Officer and principal financial officer | Appointed | 2023-12-29 |
| Jean-Jacques Bienaimé | Class II director | Appointed | 2023-11-08 |
| Clay B. Siegall, Ph.D. | Chairman and CEO | Appointed | 2023-10-04 |
| James Boylan | Class III Director | Appointed | 2023-10-04 |
| Franklyn Prendergast | Class II Director | Appointed | 2023-10-04 |
| Bruce Turner | Chief Strategy Officer | Appointed | 2023-10-04 |
| Isaac Barchas | Class II Director and Lead Independent Director | Appointed | 2023-10-04 |
| Corleen Roche | Chief Financial Officer | Appointed | 2023-10-04 |
| Sandra Stoneman | Chief Legal Officer and General Counsel | Appointed | 2023-10-04 |
| Matthew Robinson | Chief Discovery Officer, Biology | Appointed | 2023-10-04 |
| Clay Siegall | Chief Executive Officer, President, Chairman of the Board and Class I Director | Appointed | 2023-10-04 |
| Dennis Giesing | Immunome's former Chief Development Officer | Terminated | 2023-10-04 |
| Jack Higgins | Chief Scientific Officer | Appointed | 2023-10-04 |
| Purnanand D. Sarma | Immunome's board of directors and any respective committee membership of Immunome's board of directors | Resigned | 2023-10-04 |
| Purnanand D. Sarma | officer and employee of Immunome | Resigned | 2023-10-04 |
| Michael Lefenfeld | Immunome's board of directors and any respective committee membership of Immunome's board of directors | Resigned | 2023-10-04 |
| John LaMattina | Immunome's board of directors and any respective committee membership of Immunome's board of directors | Resigned | 2023-10-04 |
| Richard Baron | Immunome's board of directors and any respective committee membership of Immunome's board of directors | Resigned | 2023-10-04 |
| Michael Rapoport | Immunome's board of directors and any respective committee membership of Immunome's board of directors | Resigned | 2023-10-04 |